Display options
Cite
Cook SF, Bies RR. Disease Progression Modeling: Key Concepts and Recent Developments. Curr Pharmacol Rep. 2016;2(5):221-230doi: 10.1007/s40495-016-0066-x.
Cook, S. F., & Bies, R. R. (2016). Disease Progression Modeling: Key Concepts and Recent Developments. Current pharmacology reports, 2(5), 221-230. https://doi.org/10.1007/s40495-016-0066-x
Cook, Sarah F, and Bies, Robert R. "Disease Progression Modeling: Key Concepts and Recent Developments." Current pharmacology reports vol. 2,5 (2016): 221-230. doi: https://doi.org/10.1007/s40495-016-0066-x
Cook SF, Bies RR. Disease Progression Modeling: Key Concepts and Recent Developments. Curr Pharmacol Rep. 2016 Oct;2(5):221-230. doi: 10.1007/s40495-016-0066-x. Epub 2016 Aug 15. PMID: 28936389; PMCID: PMC5602534.
Copy Download .nbib Format: NLM
Share it on

Curr Pharmacol Rep. 2016 Oct;2(5):221-230. doi: 10.1007/s40495-016-0066-x. Epub 2016 Aug 15.

Disease Progression Modeling: Key Concepts and Recent Developments.

Current pharmacology reports

Sarah F Cook, Robert R Bies

Affiliations

  1. Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, 445 Kapoor Hall, Buffalo, NY 14214, USA.
  2. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
  3. Centre for Addiction and Mental Health, University of Toronto, 1001 Queen Street West, Toronto, ON M6J 1H4, Canada.

PMID: 28936389 PMCID: PMC5602534 DOI: 10.1007/s40495-016-0066-x

Abstract

Disease modeling involves the use of mathematical functions to describe quantitatively the time course of disease progression. In order to characterize the natural progression of disease, these models generally incorporate longitudinal data for some biomarker(s) of disease severity or can incorporate more direct measures of disease severity. Disease models are also often linked to pharmacokinetic-pharmacodynamic models so that the influence of drug treatment on disease progression can be quantified and evaluated. Regulatory agencies have embraced disease progression models as powerful tools that can be used to improve drug development productivity. This article provides a brief overview of key concepts in disease progression modeling followed by illustrative examples from models for Alzheimer's disease. Finally, recent novel applications in which disease progression models have been linked to cost-effectiveness analysis and genomic analysis are described.

Keywords: clinical pharmacology; disease progression; drug development; modeling and simulation; pharmacometrics

References

  1. J Alzheimers Dis. 2013;37(1):173-83 - PubMed
  2. Alzheimers Dement. 2015 Oct;11(10):1212-21 - PubMed
  3. Br J Soc Clin Psychol. 1967 Dec;6(4):278-96 - PubMed
  4. J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1143-9 - PubMed
  5. Genet Epidemiol. 2014 Sep;38 Suppl 1:S74-80 - PubMed
  6. CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):374-85 - PubMed
  7. Alzheimers Dement. 2010 Jan;6(1):39-53 - PubMed
  8. Alzheimers Dement. 2015 Mar;11(3):332-84 - PubMed
  9. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11471-5 - PubMed
  10. Annu Rev Med. 2008;59:1-12 - PubMed
  11. J Clin Oncol. 2009 Sep 1;27(25):4103-8 - PubMed
  12. Schizophr Res. 2011 Nov;132(2-3):108-13 - PubMed
  13. J Intern Med. 2014 Mar;275(3):251-83 - PubMed
  14. CPT Pharmacometrics Syst Pharmacol. 2013 Jul 10;2:e54 - PubMed
  15. J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):581-98 - PubMed
  16. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):119-29 - PubMed
  17. J Pharmacokinet Pharmacodyn. 2015 Aug;42(4):315-32 - PubMed
  18. Annu Rev Pharmacol Toxicol. 2009;49:291-301 - PubMed
  19. Clin Pharmacokinet. 2008;47(7):417-48 - PubMed
  20. J Clin Pharmacol. 2012 May;52(5):629-44 - PubMed
  21. Clin Pharmacol Ther. 2009 Aug;86(2):167-74 - PubMed
  22. Genet Epidemiol. 2014 Sep;38 Suppl 1:S68-73 - PubMed
  23. CPT Pharmacometrics Syst Pharmacol. 2014 Oct 22;3:e142 - PubMed
  24. Arch Neurol. 1991 Apr;48(4):383-8 - PubMed
  25. Bioinformatics. 2003 Mar 1;19(4):524-31 - PubMed
  26. N Engl J Med. 2000 Oct 12;343 (15):1054-63 - PubMed
  27. J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):479-98 - PubMed
  28. Med Decis Making. 2013 Aug;33(6):780-92 - PubMed
  29. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11466-70 - PubMed
  30. Cancer Chemother Pharmacol. 2012 Apr;69(4):881-90 - PubMed
  31. Br J Clin Pharmacol. 2007 May;63(5):595-613 - PubMed
  32. Eur J Clin Pharmacol. 1994;47(1):17-23 - PubMed
  33. J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):63-80 - PubMed
  34. Clin Pharmacol Ther. 2012 Jul;92(1):125-31 - PubMed
  35. CPT Pharmacometrics Syst Pharmacol. 2012 Nov 14;1:e14 - PubMed
  36. Clin Pharmacol Ther. 2015 Mar;97(3):210-4 - PubMed
  37. BMC Syst Biol. 2010 Jun 29;4:92 - PubMed
  38. J Neurol Sci. 1999 Oct 31;169(1-2):13-21 - PubMed
  39. Bone. 2010 Jan;46(1):49-63 - PubMed
  40. Alzheimers Dement. 2011 Mar;7(2):151-60 - PubMed
  41. Am J Respir Crit Care Med. 2014 Sep 15;190(6):619-27 - PubMed
  42. Br J Clin Pharmacol. 2012 Aug;74(2):267-83 - PubMed
  43. CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00020 - PubMed
  44. J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):281-311 - PubMed
  45. CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):386-95 - PubMed
  46. Int J Technol Assess Health Care. 2012 Oct;28(4):374-81 - PubMed
  47. Clin Pharmacol Ther. 2000 Nov;68(5):568-77 - PubMed
  48. Clin Pharmacol Ther. 2007 Jul;82(1):21-32 - PubMed
  49. Neuropsychiatr Dis Treat. 2014 May 24;10:929-52 - PubMed
  50. Clin Pharmacol Ther. 1993 Nov;54(5):556-66 - PubMed
  51. J Pharmacokinet Pharmacodyn. 2010 Apr;37(2):179-201 - PubMed
  52. Clin Pharmacol Ther. 2011 Dec;90(6):766-9 - PubMed
  53. Stat Med. 2013 Sep 30;32(22):3862-80 - PubMed
  54. Am J Psychiatry. 1984 Nov;141(11):1356-64 - PubMed

Publication Types

Grant support